Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.

Aims This open-label study in patients with alcohol dependence and evidence of elevated liver stiffness and/or hepatic steatosis was designed to explore the efficacy of nalmefene (18 mg) in reducing alcohol consumption and its subsequent effects on a variety of clinically relevant liver parameters....

Full description

Bibliographic Details

Published in:	Alcohol & Alcoholism Vol. 55; no. 1; pp. 63 - 71
Main Authors:	Mueller, Sebastian, Luderer, Mathias, Zhang, Doris, Meulien, Didier, Brach, Björn Steiniger, Schou, Maiken Brix
Format:	clinical trial research tables/charts Journal Article
Published:	Oxford University Press / USA Jan2020
Online Access:	View this record in EBSCOhost